ÂÜÀòÂÒÂ×

Nabil Zeidan, Ph.D., is a Lead Scientist at CCRM, specializing in iPSC-derived cell and gene therapy since September 2023. Prior experience includes serving as a Scientist at Notch Therapeutics, where optimization and validation of gene editing tools for genome engineering were a focus. Nabil held the position of Postdoctoral Research Scientist and Project Manager at McGill University, leading a multidisciplinary project on dendritic cell-based cancer immunotherapies. Additional roles include Guest Lecturer at McGill University and Teaching Assistant at Université de Montréal. Academic credentials include a Ph.D. in Immunology from Université de Montréal and a Master's degree in Microbiology and Immunology from American University of Beirut. Nabil's expertise encompasses bioinformatics, CRISPR/Cas9 gene-editing tools, and the differentiation of engineered iPSCs into T-cells.